Concepedia

Teresa Guida

TG

14

Publications

2.3K

Citations

13

H-Index

1995

Active since

Affiliations

Institute for Experimental Endocrinology and Oncology(Current)

University of Naples Federico II

University of Pisa

AstraZeneca (United Kingdom)

Centre National de la Recherche Scientifique

Teresa Guida is an author at Institute for Experimental Endocrinology and Oncology specializing in medicine, cell signaling, and cell biology.

Top concepts

Publications per year

1995–2015

14

Publications

14

ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida et al. · PubMed · 2002 · 570 citations

, , +17

BAY 43-9006 Inhibition of Oncogenic RET Mutants

Francesca Carlomagno, Suresh Anaganti, Teresa Guida et al. · JNCI Journal of the National Cancer Institute · 2006 · 471 citations · Full text

Transgenic Canola and Soybean Seeds with Increased Lysine

S. Carl Falco, Teresa Guida, Mary Locke et al. · Nature Biotechnology · 1995 · 388 citations

, , +9

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

Francesca Carlomagno, Teresa Guida, Suresh Anaganti et al. · Oncogene · 2004 · 252 citations

, , +7

The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes.

Francesca Carlomagno, Donata Vitagliano, Teresa Guida et al. · PubMed · 2002 · 135 citations

, , +12

Rows per page

1–5 of 14